Adrian Umpierrez
YOU?
Author Swipe
New Onset Heart Failure due to Left Atrial Myxoma Open
Left atrial myxomas are rare cardiac tumors typically presenting with constitutional, obstructive, or embolic symptoms, often managed surgically with positive clinical outcomes. We describe a case of an 88-year-old woman presenting status …
View article: A Triple Threat: Acute Systemic Lupus Erythematosus Unveiled with Hemophagocytic Lymphohistiocytosis and Toxic Epidermal Necrolysis
A Triple Threat: Acute Systemic Lupus Erythematosus Unveiled with Hemophagocytic Lymphohistiocytosis and Toxic Epidermal Necrolysis Open
A 36-year-old man with a history of arthritis, initially diagnosed as seronegative rheumatoid arthritis, developed new-onset SLE complicated by HLH and TEN. The patient presented with fevers, abdominal pain, vomiting, fatigue, rash, and si…
View article: 40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies
40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies Open
Not available.
“Transforming Care at the Bedside: The Impact of the Medicine Bedside Procedure Service on Resident Training and Patient Outcomes” Open
Background: Hospitalized patients frequently require various medical procedures, including lumbar punctures, paracenteses, and pulmonary drains, with significant annual volumes in the U.S. While bedside procedures are generally safe, their…
View article: Data from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Data from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
The dual pathway inhibitor rigosertib inhibits phosphoinositide 3-kinase (PI3K) pathway activation as well as polo-like kinase 1 (PLK1) activity across a broad spectrum of cancer cell lines. The importance of PIK3CA alterations in squamous…
View article: Supplementary Figures 1 - 7 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Supplementary Figures 1 - 7 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
PDF file - 956K, Supplementary Figure 1. A, Cellular viability of 6 sensitive and 5 resistant cell lines at 1.0μM rigosertib treatment as measured by SRB assay; Supplementary Figure 2. Proliferation of 2 rigosertib-sensitive (584 and HN11)…
View article: Supplementary Figure Legend from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Supplementary Figure Legend from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
PDF file - 64K
View article: Data from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Data from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
The dual pathway inhibitor rigosertib inhibits phosphoinositide 3-kinase (PI3K) pathway activation as well as polo-like kinase 1 (PLK1) activity across a broad spectrum of cancer cell lines. The importance of PIK3CA alterations in squamous…
View article: Supplementary Figure Legend from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Supplementary Figure Legend from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
PDF file - 64K
View article: Supplementary Tables 1 - 4 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Supplementary Tables 1 - 4 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
PDF file - 112K, Supplementary Table 1. Cell Line GSEA; Supplementary Table 2. Cell Line Mutation Status; Supplementary Table 3. PIK3CA Amplification in the Orthotopically Implanted Cell Lines; Supplementary 4 PIK3CA Amplification in the D…
View article: Supplementary Tables 1 - 4 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Supplementary Tables 1 - 4 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
PDF file - 112K, Supplementary Table 1. Cell Line GSEA; Supplementary Table 2. Cell Line Mutation Status; Supplementary Table 3. PIK3CA Amplification in the Orthotopically Implanted Cell Lines; Supplementary 4 PIK3CA Amplification in the D…
View article: Supplementary Figures 1 - 7 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Supplementary Figures 1 - 7 from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas Open
PDF file - 956K, Supplementary Figure 1. A, Cellular viability of 6 sensitive and 5 resistant cell lines at 1.0μM rigosertib treatment as measured by SRB assay; Supplementary Figure 2. Proliferation of 2 rigosertib-sensitive (584 and HN11)…
View article: Ileitis in Adult Multisystem Inflammatory Syndrome: A Case Report
Ileitis in Adult Multisystem Inflammatory Syndrome: A Case Report Open
Multisystem inflammatory syndrome (MIS) can manifest with nonspecific gastrointestinal symptoms, fever, shock, and cardiovascular dysfunction. Compared with children, MIS in adults (MIS-A) is rare. We present a definitive case of MIS-A (ba…